Genkyotex

About:

Genkyotex develops innovative drugs to block the NOX enzymes that produce oxygen radicals.

Website: http://www.genkyotex.com

Twitter/X: genkyotex_off

Top Investors: Andera Partners, VI Partners, Edmond de Rothschild Private Equity, Vesalius Biocapital Partners, MP Healthcare Venture Management

Description:

Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage. Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.